Delivery Order SPE2DB20D3103-SPE2DB25FQ1Y5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $9,481.53 for UBRELVY 100 mg tablets (16 unit dose packages) on August 22, 2025, with completion targeted for August 25, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a $2,051.65 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose) on September 8, 2025, with completion scheduled for September 9, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The performance location is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $8,959.34 to AmerisourceBergen Drug Corp for the supply of UBRELVY 100 mg tablets in unit dose packages of 10 units. The contract, issued on August 13, 2025, with an ultimate completion date of August 14, 2025, operates under a firm fixed price arrangement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performing location for this pharmaceutical supply delivery. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10-count). This competitively awarded, non-set-aside contract carries a ceiling value of $10,509.46 under a firm fixed price arrangement with an ultimate completion date of September 4, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of UBRELVY 50 mg tablets (10-count unit dose packaging) with a ceiling value of $4,919.80 and an ultimate completion date of August 4, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for UBRELVY 100 mg tablet unit dose packs (16-count) with a ceiling value of $1,488.85. This competitive award, executed under firm fixed-price terms with no set-aside designation, is scheduled for completion by September 2, 2025. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,381.64 for UBRELVY 50 MG tablets (10-unit dose packaging) on September 8, 2025, with completion scheduled for September 9, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through...
- The Defense Logistics Agency awarded a $3,188.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16 unit dose packages) on September 8, 2025, with a completion date of September 9, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $2,126.74 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose tablets) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed price contract, which is not set-aside, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated as SPE2DX, valued at $999,999,999.00 and running through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ1Y5Delivery Order
The Defense Logistics Agency (DLA) awarded a $3,430.55 delivery order to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 units) on September 8, 2025, with an ultimate completion date of September 9, 2025. This is a firm fixed-price, non-set-aside contract for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The contract demonstrates AmerisourceBergen Drug Corp's capability to meet federal procurement requirements through open competition, with a portfolio encompassing specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains in support of the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/8/25 |